Dermapharm Holding SE

DMP

DE000A2GS5D8

Pharmaceuticals

Real-time Estimate Tradegate Other stock markets 09:00:02 16/07/2024 BST			5-day change	1st Jan Change
35.92 ^EUR	+0.35%		+1.13%	-15.21%

06-27	Dermapharm Holding SE Approves Dividend	CI
06-27	Dermapharm Holding SE Provides Earnings Guidance for the Year 2024	CI

Dermapharm Holding SE Provides Earnings Guidance for the Year 2024

June 27, 2024 at 05:15 pm

Dermapharm Holding SE provided earnings guidance for the year 2024. For the year, the company expects consolidated revenue to be between EUR 1,170 million to EUR 1,210 million.

Latest news about Dermapharm Holding SE

Dermapharm Holding SE Approves Dividend	06-27	CI
Dermapharm Holding SE Provides Earnings Guidance for the Year 2024	06-27	CI
Jefferies lowers target for Dermapharm to 51 euros - 'Buy'	06-06	DP
DERMAPHARM : Jefferies reiterates its Buy rating	06-06	ZD
Drug manufacturer Dermapharm starts the new year with declines	05-15	DP
Dermapharm Holding SE Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
WDH/Pharmaceuticals manufacturer Dermapharm starts the new year with declines	05-15	DP
DERMAPHARM : Berenberg keeps its Buy rating	04-04	ZD
Dermapharm Holding SE Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Dpa-AFX Overview: COMPANIES from 14.03.2024 - 15:15	03-14	DP
Dermapharm looks cautiously into the future - missing Covid business	03-14	DP
DERMAPHARM : Berenberg reaffirms its Buy rating	12-07	ZD
DERMAPHARM : Berenberg reiterates its Buy rating	11-16	ZD
Dpa-AFX Overview: COMPANIES from 15.11.2023 - 15:15	11-15	DP
Dermapharm grows thanks to new subsidiary - nutritional supplements in demand	11-15	DP
DERMAPHARM : Jefferies reiterates its Buy rating	11-15	ZD
Dermapharm with leap in sales - growth driver Arkopharma	11-15	RE
Dermapharm Holding SE Reports Earnings Results for the Nine Months Ended September 30, 2023	11-15	CI
Dermapharm grows thanks to subsidiary Arkopharma and dietary supplements	11-15	DP
DERMAPHARM : Buy rating from Berenberg	19/10/23	ZD
DERMAPHARM : Berenberg maintains a Buy rating	21/09/23	ZD
Dermapharm Holding SE Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	29/08/23	CI
DERMAPHARM : Jefferies keeps its Buy rating	29/08/23	ZD
Dermapharm move to SDax top - Jefferies praises profitability	16/08/23	DP
Dermapharm becomes more optimistic after first half-year - share price jumps	16/08/23	DP

Dermapharm Holding SE is a Germany-based company engaged in manufacturing of patent-free branded pharmaceuticals. The Company operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. It holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The Company offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. It is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.

Sector

Pharmaceuticals

Calendar

26/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Dermapharm Holding SE

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

35.8 EUR

Average target price

50.12 EUR

Spread / Average Target

+40.01%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
DERMAPHARM HOLDING SE	-15.21%	2.1B
ELI LILLY AND COMPANY	+63.05%	856B
NOVO NORDISK A/S	+39.09%	631B
JOHNSON & JOHNSON	-4.78%	359B
MERCK & CO., INC.	+17.52%	325B
ABBVIE INC.	+8.43%	297B
ASTRAZENECA PLC	+13.68%	244B
ROCHE HOLDING AG	+5.32%	234B
NOVARTIS AG	+16.53%	226B
AMGEN INC.	+14.63%	177B

Other Pharmaceuticals